Merck and Samsung Bioepis announced the approval of a biosimilar version of Amgen's immunology medicine Enbrel by the Ministry of Food and Drug Safety in Korea.
The Korean approval of biosimilar Brenzys is the first product approval under Merck’s collaboration with Samsung Bioepis. Samsung Bioepis is a joint venture between Samsung and U.S. biotech Biogen.
Brenzys is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and psoriasis in adult patients. Merck plans to launch the biosimilar in South Korea by the end of this year or early 2016.
Read the Business Wire article